Out-of-Pocket Cost of Spinal Muscular Atrophy Gene Therapies Among Commercially Insured Patients

Maria Sckaff; Ilina C. Odouard; Jeromie Ballreich; Gerard F. Anderson; Mariana P. Socal

doi:10.1001/jamapediatrics.2026.0641

April 13, 2026JAMA Pediatrics

Out-of-Pocket Cost of Spinal Muscular Atrophy Gene Therapies Among Commercially Insured Patients

View at Publisher

Ask AI

Bookmark

Share

Key Points

To assess the insurance coverage and out-of-pocket costs associated with spinal muscular atrophy gene therapies.
Cross-sectional study design
Evaluation of commercial insurance data
Analysis of patient spending from 2021-2022
Overall out-of-pocket costs for patients using SMA therapies were substantial
Variations in costs were observed across different therapies
Insurance coverage significantly influenced patient expenditure

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Cross-sectional study evaluates insurance and out-of-pocket costs for SMA gene therapies, indicating financial impact on patients.

Abstract

This cross-sectional study evaluates insurance and patient spending for the spinal muscular atrophy medications nusinersen, onasemnogene abeparvovec-xioi, and risdiplam from 2021 through 2022.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sckaff et al. (2026) studied this question.

synapsesocial.com/papers/69df2cb9e4eeef8a2a6b1ffc https://doi.org/10.1001/jamapediatrics.2026.0641

View at Publisher

Ask AI

Bookmark

Share

Out-of-Pocket Cost of Spinal Muscular Atrophy Gene Therapies Among Commercially Insured Patients

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Out-of-Pocket Cost of Spinal Muscular Atrophy Gene Therapies Among Commercially Insured Patients

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading